Vestmark Advisory Solutions’s Recursion Pharmaceuticals RXRX Stock Holding History

Vestmark Advisory Solutions’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.6M	Sell	708,858 -18,128	-2%	-$60.4K	0.02%	597
2026 Q1	$2.23M	Buy	726,986 +122,230	+20%	+$472K	0.02%	582
2025 Q4	$2.47M	Sell	604,756 -16,303	-3%	-$80.7K	0.03%	514
2025 Q3	$3.03M	Sell	621,059 -718,080	-54%	-$3.77M	0.06%	331
2025 Q2	$6.78M	Buy	1,339,139 +632,900	+90%	+$3.11M	0.1%	154
2025 Q1	$3.74M	Sell	706,239 -138,915	-16%	-$1.01M	0.1%	244
2024 Q4	$6.36M	Buy	845,154 +112,221	+15%	+$754K	0.22%	92
2024 Q3	$4.83M	Sell	732,933 -51,964	-7%	-$373K	0.18%	115
2024 Q2	$5.89M	Sell	784,897 -115,122	-13%	-$1M	0.25%	86
2024 Q1	$8.97M	Buy	900,019 +427,763	+91%	+$4.76M	0.39%	55
2023 Q4	$4.66M	Buy	+472,256	New	+$3.37M	0.24%	102

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vestmark Advisory Solutions's RXRX Position: Q2 2026 in Review

Vestmark Advisory Solutions reduced its Recursion Pharmaceuticals (RXRX) stake by 2.5% in Q2 2026, selling an estimated $60.4K and leaving 708,858 shares worth $2.6M. The position accounts for 0.02% of the portfolio, ranked #597.

Vestmark Advisory Solutions first reported a position in RXRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $8.97M in Q1 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Vestmark Advisory Solutions held 708,858 shares of Recursion Pharmaceuticals worth $2.6M as of Q2 2026.
Vestmark Advisory Solutions sold 18,128 Recursion Pharmaceuticals shares in Q2 2026, an estimated $60.4K.
Recursion Pharmaceuticals made up 0.02% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #597 holding.
Vestmark Advisory Solutions first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Vestmark Advisory Solutions's Recursion Pharmaceuticals position peaked at $8.97M in Q1 2024.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.